Event > Conference >
EUROTOX 2024
The 58th Congress of the European Toxicologists and European Societies of Toxicology will take place this year under the theme “Toxicology – A Quest for safe Chemicals and Medicines.”
Thank you for visiting us at EUROTOX!
Our dedicated team will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you at EUROTOX 2024!
We look forward to introducing you to our PhysioMimix® suite of hardware, consumables, assay protocols and contract research services. Discover how our solutions deliver clinically relevant mechanistic data that enable you to design cost-efficient in vivo studies (using fewer animals) and improve your ability to predict clinical outcomes.
Plus, meet the new game-changing product in our PhysioMimix OOC range of microphysiological systems, the PhysioMimix Single-organ Higher Throughput (HT) System and associated Multi-chip Liver-48 plate.
Industry Hosted Session
Lost in translation: Developing predictive liver toxicology assays using microphysiological systems
When considering drug design and development, understanding the interaction of drugs with the liver is crucial. Not only does the liver play a central role in metabolism, but it is one of the most commonly affected organs in adverse toxic events. Drug-induced liver injury (DILI) is a leading cause of drug attrition in drug discovery, mainly due to complex, human-specific mechanistic events that cannot be captured in vivo or in simple in vitro models due to physiological, or human relevance limitations. With the advent of more human-specific modalities and shifts to the regulatory landscape, it is increasingly important to incorporate new alternative methodologies (NAMs) into the preclinical toolbox to more accurately predict human outcomes.
In this session, learn how PhysioMimix® human liver microphysiological systems (MPS), also known as Liver-on-a-chip, can be applied to identify otherwise missed DILI risks. We will introduce two Liver MPS formats – the PhysioMimix Multi-chip Liver-12 plate and the higher throughput Liver-48 plate – and indicate their applications in drug discovery and development workflows. We will demonstrate how the human Liver MPS can be applied to detect acute and chronic DILI, whilst also elucidating mechanism of action. The use of preclinical animal MPS for understanding species-specific toxicity, animal safeguarding and derisking preclinical studies will be discussed.
The presentation provides an understanding of how the early adoption of MPS into the drug discovery pipeline allows for more refined preclinical experimental design by narrowing down compound selection ahead of in vivo animal studies, and how to be better prepared for the clinic.
Key learnings:
- Utilization of MPS to de-risk DILI within preclinical drug discovery & development
- The benefits of unlocking DILI mechanism of action
- How to study acute and chronic DILI in vitro
- The use of animal MPS to save costs and minimize animal use
Date: Tuesday 10 September. 2024
Time: 12:00-13:00
Location: Arkaden 7 (second floor)
Presenters: Dr. Emily Richardson, CN Bio, and Dr. Tomasz Kostrzewski, CN Bio
CN Bio Poster
Bridging the gap: human and preclinical animal microphysiological systems for assessing drug-induced liver injury during drug discovery
Poster board: P02-33
Abstract ID: 832
Presented by: Christiana Skarlatopoulou, CN Bio
Date / track: Monday 9 September, P02 | New approach methodologies: 3D models, stem cells, organ-on-a-chip, microfluidics
Meet the CN Bio Team at EUROTOX!
Emily
Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix® lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.
Christiana
Christiana Skarlatopoulou is a Scientist at CN Bio in the Contract Research team. She graduated from the Biomedical and Molecular Research MRes program at King’s College London, with a focus on tissue engineering and hepatic fibrosis using organoids. Prior to her master’s, she worked as a research technician for Twin Research and Genetic Epidemiology at King’s College London, mainly performing biobank duties. Christiana gained a variety of biological and research skills during her BSc in Biology at the University of Regensburg, Germany. Since joining CN Bio, her focus has been on the delivery of contract research projects utilizing the PhysioMimix® OOC microphysiological systems and working on the NASH and DILI models.
Tomasz
Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.
Adrian
A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN Bio as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.